Robert M. Thomas, Jr. of Thomas and Associates, Boston, MA -- Bob Thomas: Whistleblower, qui tam law, false claims act, fraud, internal investigations and more.

Set the Record Straight.
We are trial lawyers focusing on fraud cases: qui tam whistle-blower representation, internal investigations, white collar litigation, and criminal defense. Thomas & Associates has represented clients in False Claims Act cases that have led to the recovery of over $ 3 billion for U.S. taxpayers, and millions to our clients. We know how to set the record straight. Learn more»

ROBERT M. THOMAS, JR.
AND ASSOCIATES

· Firm Overview
· Practice Areas
· Contact Us



		· Whistleblower Representation · False Claims Act and · Qui Tam Litigation
		The False Claims Act is the primary tool to help expose fraud in government programs from healthcare to homeland defense, from public utilities to public works, while protecting those who step forward. Access our Whistleblower Info Center
		*learn more »*



		Internal Investigations of Fraud & Corruption
		Thomas & Associates has a proven track record conducting internal investigations on behalf of labor unions, banks, and companies. Bob Thomas serves as special prosecutor of labor corruption cases across the country, involving primarily anti-racketeering (RICO) cases.
		*learn more »*



		· Civil and Criminal Litigation · Grand Jury Investigations · White Collar Criminal Defense
		Extensive courtroom experience is the foundation for Thomas & Associates success in criminal law and civil litigation. We represent individuals in criminal grand jury investigations and complex white-collar fraud matters.
		*learn more »*

NEWS AND EVENTS

Commemorating the 25th Anniversary of the False Claims Act

Download the 25th Anniversary Brochure prepared by
the Taxpayers Against Fraud Education Fund (PDF)

ELAN & EISAI NEWS

FEB. 28, 2011: Elan Convicted Over Marketing of Zonegran

Elan pleads guilty to misdemeanor violation of federal law in the marketing of epilepsy drug.

DEC. 15, 2010: Elan & Eisai Whistleblower Cases Settle for $203 Million and $11 Million

Law firms assist successful prosecution of off-label marketing cases. The case involved allegations of improper "off-label" marketing of the anti-seizure drug Zonegran, first by Irish pharmaceutical manufacturer Elan Corp., then later by Japanese pharmaceutical company Eisai, Inc., which bought the rights to the drug from Elan in 2004.

FOREST LABORATORIES FRAUD NEWS

MAR. 2, 2011: Forest Pharmaceuticals Sentenced to Pay $164 Million for Criminal Violations

Forest Pharmaceuticals Inc. was sentenced today by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company’s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce.

SEPT. 15, 2010: Forest paying $313 million in government probe

Forest Laboratories Inc. said Wednesday it finalized a deal for $313 million with the Justice Department in fines and a settlement over allegations it gave kickbacks to doctors who prescribed its antidepressants.

RELATED NEWS COVERAGE

View latest news stories and analysis on this topic as aggregated by Google News

PREVIOUS ANNOUNCEMENTS

Judge Nathaniel Gorton denied Forest's motion to dismiss relator's employment claim.

Read the United States' DOJ Announcement. (PDF)
A Complaint was unsealed today in U.S. District Court in Massachusetts against a New York pharmaceutical company for alleged False Claims Act violations arising from the company’s marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying kickbacks to induce physicians to prescribe the drugs.
Complete Press Release. (PDF)

Read the United States' Complaint. (PDF)

AMGEN ARANESP KICKBACK NEWS
Boston attorneys Suzanne E. Durrell, Robert M. Thomas, Jr., and Rory Delaney, and Los Angeles attorneys Charles F. Kester and Lawrence M. Isenberg of the law firm Kester & Isenberg, announced today the filing of an amended complaint against biotechnology company Amgen Inc. and others, in a case pending before United District Court Judge William G. Young in Boston. The amended complaint, filed pursuant to federal and state False Claims Acts by Relator Kassie Westmoreland, a former Amgen employee, is filed the same day as a consolidated complaint in intervention brought by fifteen state Attorney General offices. These state plaintiffs recently filed notices of intervention in Ms. Westmoreland's lawsuit.
Related Press Release | (PDF)
NEW: 4th Amended Complaint (PDF)
Amended Complaint (PDF) | Multistate Amgen Complaint (PDF)

5 Amgen Execs Plead the Fifth on Alleged Kickbacks Described in Spreadsheet
BNet

Amgen sued by California and 14 other states over anemia drug
Los Angeles Times

Amgen Is Accused of Illegal Kickbacks
New York Times

View latest news stories and blog analysis on this topic as aggregated by Google News

St. Jude Medical

The U.S. Justice Department said it wants to intervene in a lawsuit against St. Jude Medical, Inc. in which a former worker accused the heart-device maker of using medical studies to pay kickbacks and boost product usage.

RELATED STORIES

US To Intervene In Alleged St Jude Kickback Case
NASDAQ, Dow Jones Newswire

U.S. Can Join St. Jude Medical False Claims Case
Bloomberg Businessweek

$2.3 BILLION PFIZER SETTLEMENT NEWS

Pfizer Inc. will pay approximately $2.3 billion dollars to settle claims it misbranded one of its pain killer drugs, promoted the off label use of numerous drugs, and paid kickbacks to doctors to induce or reward the prescription of Pfizer drugs. Boston attorneys Suzanne E. Durrell, Robert M. Thomas, Jr. and Rory Delaney represent one of the whistleblowers, Blair Collins, who brought kickback allegations regarding the drugs Lipitor, Norvasc, Viagra, Zithromax, and Zyrtec, and whose information helped form the basis for today's settlement.
Read the Pfizer Settlement Press Release | (PDF)

Official DOJ Pfizer Announcement

RELATED STORIES
VIDEO: Drug maker Pfizer to pay record $2.3 billion penalty over promotions
(NECN: Washington) - Pfizer Inc., the world's largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription drug promotions. The...

Pfizer To Pay $2.3B To Settle Case On Drug Marketing - DOJ
Wall Street Journal - WASHINGTON (Dow Jones)--Pfizer Inc. (PFE) has agreed to pay $2.3 billion to settle charges that it illegally ...